{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:55:59Z","timestamp":1791168959009,"version":"4.1.0"},"reference-count":167,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T00:00:00Z","timestamp":1416441600000},"content-version":"vor","delay-in-days":1998,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.bbadis.2009.04.001","type":"journal-article","created":{"date-parts":[[2009,4,11]],"date-time":"2009-04-11T08:20:51Z","timestamp":1239438051000},"page":"506-520","source":"Crossref","is-referenced-by-count":135,"title":["Mouse models of Huntington's disease and methodological considerations for therapeutic trials"],"prefix":"10.1016","volume":"1792","author":[{"given":"Robert J.","family":"Ferrante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2009.04.001_bib1","series-title":"On chorea","first-page":"317","author":"Huntington","year":"1872"},{"key":"10.1016\/j.bbadis.2009.04.001_bib2","first-page":"83","article-title":"Huntington's chorea: current neuropathological status, In Huntington's disease","volume":"23","author":"Bruyn","year":"1979","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib3","first-page":"995","article-title":"Nue anatomische befunde bei paralysis agitans und bei chronischer progessiver chorea","volume":"27","author":"Jergelsma","year":"1908","journal-title":"Neurol. Centralbl."},{"key":"10.1016\/j.bbadis.2009.04.001_bib4","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199405193302001","article-title":"A worldwide study of Huntington's disease mutation: the sensitivity and specificity of measuring CAG repeats","volume":"330","author":"Kremer","year":"1994","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.bbadis.2009.04.001_bib5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/ng1093-168","article-title":"De novo expansion of a (CAG)n repeat in sporadic Huntington's disease","volume":"5","author":"Myers","year":"1993","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbadis.2009.04.001_bib6","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1212\/WNL.57.4.658","article-title":"The Huntington Study Group, clinical markers of early disease in persons near onset of Huntington's disease","volume":"57","author":"Paulsen","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2009.04.001_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/1531-8249(200101)49:1<29::AID-ANA7>3.0.CO;2-B","article-title":"Quantitative neuropathological changes in presymptomatic Huntington's disease","volume":"49","author":"Gomez-Tortosa","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib8","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/01.wnl.0000341768.28646.b6","article-title":"Automatic detection of preclinical neurodegeneration: presymptomatic Huntington's disease","volume":"72","author":"Kloppel","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2009.04.001_bib9","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/jnnp.48.6.530","article-title":"Late onset Huntington's disease","volume":"48","author":"Myers","year":"1985","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bbadis.2009.04.001_bib10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1001\/archneur.1963.00460090050005","article-title":"Huntington's chorea in childhood","volume":"9","author":"Jervis","year":"1963","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/mds.1056","article-title":"Impact of Huntington's disease on quality of life","volume":"16","author":"Helder","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbadis.2009.04.001_bib12","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2009.04.001_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0896-6273(03)00569-5","article-title":"Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport","volume":"40","author":"Szebenyi","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.bbadis.2009.04.001_bib14","doi-asserted-by":"crossref","first-page":"12171","DOI":"10.1073\/pnas.2034961100","article-title":"Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease","volume":"100","author":"Trushina","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2009.04.001_bib15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","article-title":"Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules","volume":"118","author":"Gauthier","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2009.04.001_bib16","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/ana.410360604","article-title":"Trinucleotide repeat expansion in neurological disease","volume":"36","author":"La Spada","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib17","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1098\/rstb.1999.0452","article-title":"Polyglutamine pathogenesis","volume":"354","author":"Ross","year":"1999","journal-title":"Philos. Trans. R Soc. Lond. B. Biol. Sci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0079-6603(00)66029-4","article-title":"The intrinsically unstable life of DNA triplet repeats associated with human hereditary disorders","volume":"66","author":"Bowater","year":"2001","journal-title":"Prog. Nucleic Acid Res. Mol. Biol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1086\/302269","article-title":"Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold","volume":"64","author":"Paulson","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbadis.2009.04.001_bib20","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/hmg\/10.10.1049","article-title":"Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release","volume":"10","author":"Jana","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2009.04.001_bib21","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1093\/hmg\/9.13.2009","article-title":"Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity","volume":"9","author":"Jana","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2009.04.001_bib22","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/hmg\/8.4.673","article-title":"Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3\/MJD and suppression of polyglutamine aggregation in vitro","volume":"8","author":"Chai","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2009.04.001_bib23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0166-2236(00)01609-X","article-title":"Transcriptional dysregulation in Huntington's disease","volume":"23","author":"Cha","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib24","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1098\/rstb.1999.0455","article-title":"Evidence for a recruitment and sequestration mechanism in Huntington's disease","volume":"354","author":"Preisinger","year":"1999","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib25","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2009.04.001_bib26","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999","article-title":"Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology","volume":"19","author":"Gutekunst","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib27","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1531-8249(199912)46:6<842::AID-ANA6>3.0.CO;2-O","article-title":"Huntingtin aggregates may not predict neuronal death in Huntington's disease","volume":"46","author":"Kuemmerle","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrn1386","article-title":"Experimental therapeutics in transgenic mouse models of Huntington's disease","volume":"5","author":"Beal","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib29","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/mds.20979","article-title":"Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures","volume":"21","author":"Rosas","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbadis.2009.04.001_bib30","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/brain\/awn025","article-title":"Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity","volume":"131","author":"Rosas","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.bbadis.2009.04.001_bib31","series-title":"Movement Disorders: Neurologic Principles and Practice","first-page":"502","article-title":"Neuropathology and pathophysiology of Huntington's disease","author":"Hersch","year":"2004"},{"key":"10.1016\/j.bbadis.2009.04.001_bib32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington's disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib33","first-page":"24","article-title":"Patterns of cell loss in Huntington's disease","volume":"10","author":"Kowall","year":"1987","journal-title":"T.I.N.S."},{"key":"10.1016\/j.bbadis.2009.04.001_bib34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0006-8993(87)90694-9","article-title":"Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease","volume":"411","author":"Ferrante","year":"1987","journal-title":"Brain Res."},{"key":"10.1016\/j.bbadis.2009.04.001_bib35","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1126\/science.2931802","article-title":"Selective sparing of a class of striatal neurons in Huntington's disease","volume":"230","author":"Ferrante","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2009.04.001_bib36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0304-3940(86)90634-8","article-title":"Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum","volume":"71","author":"Ferrante","year":"1986","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbadis.2009.04.001_bib37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/brain\/97.1.457","article-title":"Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia","volume":"97","author":"Bird","year":"1974","journal-title":"Brain"},{"key":"10.1016\/j.bbadis.2009.04.001_bib38","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","article-title":"Differential loss of striatal projection neurons in Huntington's disease","volume":"85","author":"Reiner","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2009.04.001_bib39","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF01148468","article-title":"Localization of substance P-like immunoreactivity in neurons and nerve microscopic study","volume":"12","author":"Bolam","year":"1983","journal-title":"Neurocytol"},{"key":"10.1016\/j.bbadis.2009.04.001_bib40","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00005072-198701000-00002","article-title":"Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease","volume":"46","author":"Ferrante","year":"1987","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib41","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1523\/JNEUROSCI.11-12-03877.1991","article-title":"Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28K immunocytochemistry","volume":"11","author":"Ferrante","year":"1991","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib42","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.3155875","article-title":"Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease","volume":"227","author":"Graveland","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2009.04.001_bib43","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1523\/JNEUROSCI.19-03-00964.1999","article-title":"Mutant huntingtin expression in clonal striatal cells: dissociation on inclusion formation and neuronal survival by caspase inhibition","volume":"19","author":"Kim","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib44","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/cne.20680","article-title":"Chronology of behavioral symptoms and neuropathological sequela in R6\/2 Huntington's disease transgenic mice","volume":"490","author":"Stack","year":"2005","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib45","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(97)08360-8","article-title":"Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?","volume":"351","author":"Davies","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2009.04.001_bib46","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/cne.10295","article-title":"Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6\/2 transgenic mice","volume":"449","author":"Meade","year":"2002","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib47","doi-asserted-by":"crossref","first-page":"11402","DOI":"10.1073\/pnas.0503634102","article-title":"Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions","volume":"102","author":"Slow","year":"2005","journal-title":"Proc. Nat. Acad. Sci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib48","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.nbd.2008.03.010","article-title":"Full length mutant huntingtin is required for altered Ca signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease","volume":"31","author":"Zhang","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbadis.2009.04.001_bib49","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0092-8674(00)80464-X","article-title":"Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse","volume":"91","author":"Ordway","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2009.04.001_bib50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0092-8674(00)81781-X","article-title":"Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice","volume":"95","author":"Klement","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2009.04.001_bib51","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0092-8674(00)81782-1","article-title":"Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusion","volume":"95","author":"Sadou","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2009.04.001_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0092-8674(00)81743-2","article-title":"Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental, or beneficial?","volume":"95","author":"Sisodia","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2009.04.001_bib53","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"431","author":"Arrasate","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2009.04.001_bib54","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1126\/science.1056784","article-title":"Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity","volume":"291","author":"Nucifora","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2009.04.001_bib55","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1126\/science.292.5521.1552","article-title":"Impairment of the ubiquitin\u2013proteasome system by protein aggregation","volume":"292","author":"Bence","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2009.04.001_bib56","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nn884","article-title":"Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines","volume":"5","author":"Panov","year":"2002","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib57","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1517\/13543784.16.12.1933","article-title":"Huntington's disease: progress and potential in the field","volume":"16","author":"Stack","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bbadis.2009.04.001_bib58","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2009.04.001_bib59","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/archopht.1957.00940010205006","article-title":"The toxic effect of sodium l-glutamate on the inner layers of the retina","volume":"58","author":"Lucas","year":"1957","journal-title":"A.M.A. Arch. Ophthalmol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib60","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1523\/JNEUROSCI.04-07-01884.1984","article-title":"Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death","volume":"4","author":"Rothman","year":"1984","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib61","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/263517a0","article-title":"Duplication of biochemical changes of Huntington's chorea by intrastriatal injection of glutamic and kainic acids","volume":"263","author":"McGeer","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2009.04.001_bib62","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/263244a0","article-title":"Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea","volume":"263","author":"Coyle","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2009.04.001_bib63","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1528-1167.2008.01489.x","article-title":"Glial activation precedes seizures and hippocampal neurodegeneration in measles virus-infected mice","volume":"49","author":"Lehrmann","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.bbadis.2009.04.001_bib64","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.expneurol.2003.08.016","article-title":"Enkephalinergic striatal projection neurons become less affected by quinolinic acid than substance P-containing striatal projection neurons as rats age","author":"Sun","year":"2003","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib65","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1523\/JNEUROSCI.11-01-00147.1991","article-title":"Neurochemical characterization of excitotoxin lesions in the cerebral cortex","volume":"11","author":"Beal","year":"1991","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib66","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1006\/exnr.1993.1006","article-title":"Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization","volume":"119","author":"Ferrante","year":"1993","journal-title":"Exper. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib67","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1523\/JNEUROSCI.08-10-03901.1988","article-title":"Systemic approaches to modifying quinolinic acid striatal lesions in rats","volume":"8","author":"Beal","year":"1988","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib68","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1523\/JNEUROSCI.11-06-01649.1991","article-title":"Chronic quinolinic acid lesions in rats closely resemble Huntington's disease","volume":"11","author":"Beal","year":"1991","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib69","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/00001756-199406020-00026","article-title":"Movement disorder following excitotoxin lesions in primates","volume":"5","author":"Storey","year":"1994","journal-title":"Neuroreport"},{"key":"10.1016\/j.bbadis.2009.04.001_bib70","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ana.410310111","article-title":"Neurofilament and neural cell adhesion molecule immunocytochemistry of Huntington's disease striatum","volume":"31","author":"Nihei","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib71","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1126\/science.2841762","article-title":"NMDA receptor losses in putamen from patients with Huntington's disease","volume":"241","author":"Young","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2009.04.001_bib72","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0006-8993(78)90941-1","article-title":"Kainate-induced degeneration of neostriatal neurons: dependency upon corticostriatal tract","volume":"139","author":"McGeer","year":"1978","journal-title":"Brain Res."},{"key":"10.1016\/j.bbadis.2009.04.001_bib73","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/jnr.490040507","article-title":"Effects of cortical ablation on the neurotoxicity and receptor binding of kainic acid in striatum","volume":"4","author":"Biziere","year":"1979","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.bbadis.2009.04.001_bib74","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00001756-200101220-00025","article-title":"Role of corticostriatal and nigrostriatal inputs in malonate-induced striatal toxicity","volume":"12","author":"Meldrum","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.bbadis.2009.04.001_bib75","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1006\/exnr.1998.6918","article-title":"6-Hydroxydopamine injections into the nigrostriatal pathway attenuate striatal malonate and 3-nitropropionic acid lesions","volume":"154","author":"Maragos","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib76","doi-asserted-by":"crossref","first-page":"10116","DOI":"10.1523\/JNEUROSCI.18-23-10116.1998","article-title":"Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease","volume":"18","author":"Reynolds","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib77","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0166-2236(00)01568-X","article-title":"Neuronal cell death in Huntington's disease: a potential role for dopamine","volume":"23","author":"Jakel","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib78","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1212\/WNL.42.4.733","article-title":"Alternative excitotoxic hypotheses","volume":"42","author":"Albin","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2009.04.001_bib79","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/ana.410310202","article-title":"Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?","volume":"31","author":"Beal","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib80","series-title":"Kainic Acid as a Tool in Neurobiology","first-page":"95","article-title":"Neurotoxicity of excitatory amino acids","author":"Olney","year":"1978"},{"key":"10.1016\/j.bbadis.2009.04.001_bib81","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0006-8993(88)90765-2","article-title":"Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced","volume":"451","author":"Novelli","year":"1988","journal-title":"Brain Res."},{"key":"10.1016\/j.bbadis.2009.04.001_bib82","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0022-3565(25)24721-8","article-title":"Mechanisms underlying initiation of excitotoxicity associated with metabolic inhibition","volume":"257","author":"Zeevalk","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbadis.2009.04.001_bib83","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1111\/j.1471-4159.1985.tb07192.x","article-title":"Regional mitochondrial respiratory activity in Huntington's disease brain","volume":"44","author":"Brennan","year":"1985","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2009.04.001_bib84","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1212\/WNL.40.8.1231","article-title":"Evidence for a defect in NADH ubiquinone oxidoreductase (complex I) in Huntington's disease","volume":"40","author":"Parker","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2009.04.001_bib85","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/0140-6736(90)92242-A","article-title":"Mitochondrial function and parental sex effect in Huntington's disease","volume":"336","author":"Mann","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2009.04.001_bib86","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1042\/bst0221002","article-title":"Oxidative damage and mitochondrial dysfunction in neurodegenerative diseases","volume":"22","author":"Browne","year":"1994","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bbadis.2009.04.001_bib87","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0014-4886(72)90175-6","article-title":"Choreoathetosis and striopallidal necrosis due to sodium azide","volume":"34","author":"Mettler","year":"1972","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib88","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/j.1471-4159.1991.tb08258.x","article-title":"Aminooxyacetic acid results in excitotoxin lesions by a novel indirect mechanism","volume":"57","author":"Beal","year":"1991","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2009.04.001_bib89","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/j.1471-4159.1992.tb10080.x","article-title":"1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism","volume":"58","author":"Storey","year":"1992","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2009.04.001_bib90","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1046\/j.1471-4159.1995.64052239.x","article-title":"Involvement of free radicals in excitotoxicity in vivo","volume":"64","author":"Schulz","year":"1995","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2009.04.001_bib91","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0006-8993(94)91412-5","article-title":"Malonate produces striatal lesions by indirect NMDA receptor activation","volume":"647","author":"Henshaw","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.bbadis.2009.04.001_bib92","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1017\/S0317167100032212","article-title":"3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin","volume":"18","author":"Ludolph","year":"1991","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib93","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1073\/pnas.74.9.3767","article-title":"3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase","volume":"74","author":"Alston","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2009.04.001_bib94","first-page":"151","article-title":"3-Nitropropionic acid decreases cellular energy levels and causes neuronal degeneration in cortical explants","volume":"1","author":"Ludolph","year":"1992","journal-title":"Neurodegeneration"},{"key":"10.1016\/j.bbadis.2009.04.001_bib95","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1523\/JNEUROSCI.13-10-04181.1993","article-title":"Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid","volume":"13","author":"Beal","year":"1993","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib96","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1471-4159.1993.tb05859.x","article-title":"Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid","volume":"60","author":"Brouillet","year":"1993","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2009.04.001_bib97","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/exnr.2002.7947","article-title":"The differential vulnerability of striatal projection neurons in 3-nitropropionic acid-treated rats does not match that typical of adult-onset Huntington's disease","volume":"176","author":"Sun","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib98","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1006\/nbdi.2002.0512","article-title":"Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease","volume":"10","author":"Blum","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbadis.2009.04.001_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0306-4522(87)90322-8","article-title":"Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement","volume":"21","author":"Crossman","year":"1987","journal-title":"Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib100","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/brain\/111.5.1211","article-title":"Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism in the lentiform complex","volume":"111","author":"Crossman","year":"1988","journal-title":"Brain"},{"key":"10.1016\/j.bbadis.2009.04.001_bib101","first-page":"281","article-title":"Primate models of movement disorders of basal ganglia origin","volume":"13","author":"DeLong","year":"1990","journal-title":"T.I.N.S."},{"key":"10.1016\/j.bbadis.2009.04.001_bib102","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1006\/exnr.1998.6842","article-title":"Metabolic compromise with systemic 3-nitropropionic acid produces striatal apoptosis in Sprague\u2013Dawley rats but not in BALB\/c ByJ mice","volume":"153","author":"Alexi","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib103","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1046\/j.1471-4159.1998.70020794.x","article-title":"Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat","volume":"70","author":"Brouillet","year":"1998","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2009.04.001_bib104","doi-asserted-by":"crossref","first-page":"43245","DOI":"10.1074\/jbc.M305057200","article-title":"In vivo calpain\/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration: implication of calpain-mediated cleavage of active caspase-3","volume":"278","author":"Bizat","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2009.04.001_bib105","doi-asserted-by":"crossref","first-page":"8419","DOI":"10.1523\/JNEUROSCI.15-12-08419.1995","article-title":"Blockade of neuronal nitric oxide synthase protects against excitotoxicity in vivo","volume":"15","author":"Schulz","year":"1995","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib106","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0306-4522(96)00602-1","article-title":"Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid","volume":"79","author":"Guyot","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbadis.2009.04.001_bib107","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.1471-4159.2005.03515.x","article-title":"3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease","volume":"95","author":"Brouillet","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2009.04.001_bib108","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/S0002-9440(10)62536-9","article-title":"Mitochondrial toxin 3-nitropropionic acid induces cardiac and neurotoxicity differentially in mice","volume":"159","author":"Gabrielson","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib109","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon I of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2009.04.001_bib110","first-page":"397","article-title":"Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin","volume":"8","author":"Jenkins","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2009.04.001_bib111","doi-asserted-by":"crossref","first-page":"9112","DOI":"10.1523\/JNEUROSCI.21-23-09112.2001","article-title":"Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease","volume":"21","author":"Laforet","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib112","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ng1297-404","article-title":"Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion","volume":"17","author":"White","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbadis.2009.04.001_bib113","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/hmg\/8.1.115","article-title":"Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse","volume":"8","author":"Wheeler","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2009.04.001_bib114","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/hmg\/8.5.763","article-title":"A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice","volume":"8","author":"Shelbourne","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2009.04.001_bib115","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/hmg\/9.4.503","article-title":"Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice","volume":"9","author":"Wheeler","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2009.04.001_bib116","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/hmg\/10.2.137","article-title":"Neurological abnormalities in a knock-in mouse model of Huntington's disease","volume":"10","author":"Lin","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2009.04.001_bib117","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cne.10776","article-title":"Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats","volume":"465","author":"Menalled","year":"2003","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib118","doi-asserted-by":"crossref","first-page":"8989","DOI":"10.1523\/JNEUROSCI.1830-07.2007","article-title":"Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington's disease","volume":"27","author":"Heng","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib119","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/hmg\/5.12.1875","article-title":"Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype","volume":"5","author":"Hodgson","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2009.04.001_bib120","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/2510","article-title":"Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA","author":"Reddy","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbadis.2009.04.001_bib121","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1602\/neurorx.1.3.298","article-title":"Translating therapies for Huntington's disease from genetic animal models to clinical trials","volume":"1","author":"Hersch","year":"2004","journal-title":"NeuroRx"},{"key":"10.1016\/j.bbadis.2009.04.001_bib122","doi-asserted-by":"crossref","first-page":"415","DOI":"10.18388\/abp.2004_3581","article-title":"Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease","volume":"51","author":"Hannan","year":"2004","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib123","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.pharmthera.2005.04.008","article-title":"The therapeutic role of creatine in Huntington's disease","volume":"108","author":"Ryu","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2009.04.001_bib124","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1749-6632.1999.tb07841.x","article-title":"Metabolic and glutamatergic disturbances in the Huntington's disease transgenic mouse","volume":"893","author":"Higgins","year":"1999","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib125","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0166-4328(01)00261-3","article-title":"Evaluation of R6\/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus","volume":"126","author":"Luesse","year":"2001","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbadis.2009.04.001_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1523\/JNEUROSCI.22-02-j0006.2002","article-title":"Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene","volume":"22","author":"Rebec","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib127","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1037\/0735-7044.117.6.1233","article-title":"Exploratory activity and fear conditioning abnormalities develop early in R6\/2 Huntington's disease transgenic mice","volume":"117","author":"Bolivar","year":"2003","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib128","doi-asserted-by":"crossref","first-page":"12908","DOI":"10.1523\/JNEUROSCI.4318-07.2007","article-title":"Neuroprotective effects of synaptic modulation in Huntington's disease","volume":"27","author":"Stack","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib129","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.neuroscience.2003.08.053","article-title":"Molecular and behavioral analysis of the R6\/1 Huntington's disease transgenic mouse","volume":"122","author":"Naver","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbadis.2009.04.001_bib130","doi-asserted-by":"crossref","first-page":"8727","DOI":"10.1073\/pnas.96.15.8727","article-title":"Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity","volume":"96","author":"Hansson","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2009.04.001_bib131","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1046\/j.0953-816x.2001.01767.x","article-title":"Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of Huntington gene","volume":"14","author":"Hansson","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib132","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1471-4159.2002.00804.x","article-title":"The role of dopamine in motor symptoms in the R6\/2 transgenic mouse model of Huntington's disease","volume":"81","author":"Hickey","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2009.04.001_bib133","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1006\/exnr.2002.7885","article-title":"Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease","volume":"175","author":"Petersen","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib134","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1006\/nbdi.2002.0534","article-title":"Evidence for dysfunction of the nigrostriatal pathway in the R6\/1 line of transgenic Huntington's disease mice","volume":"11","author":"Petersen","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbadis.2009.04.001_bib135","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1046\/j.1471-4159.1998.71062642.x","article-title":"Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease","volume":"71","author":"Bogdanov","year":"1998","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2009.04.001_bib136","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1111\/j.1460-9568.2006.05198.x","article-title":"Differential susceptibility to striatal neurodegeneration induced by quinolinic acid and kainate in inbred\u2013outbred and hybrid mouse strains","volume":"24","author":"McLin","year":"2006","journal-title":"Eur.J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib137","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1046\/j.1471-4159.2001.00482.x","article-title":"Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length","volume":"78","author":"Hansson","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2009.04.001_bib138","unstructured":"S. Ramaswamy, J.L. McBride, L. Zhou, I. Han, E.M. Berry-Kravis, C.D. Herzog, M. Gasmi, R.T. Partus, J.H. Kordower, Cognitive deficits in the N171\u201382Q transgenic mouse model of Huntington's disease, Cell Transplant. Special issue for the American Society for Neural Therapy and Repair."},{"key":"10.1016\/j.bbadis.2009.04.001_bib139","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1523\/JNEUROSCI.23-06-02193.2003","article-title":"Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease","volume":"15","author":"Yu","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib140","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1073\/pnas.0508875103","article-title":"Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease","volume":"103","author":"McBride","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2009.04.001_bib141","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/j.1471-4159.2005.03036.x","article-title":"Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's disease","volume":"93","author":"Brustovetsky","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2009.04.001_bib142","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/hmg\/11.6.633","article-title":"Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers on Hdh CAG knock-in mice","volume":"11","author":"Wheeler","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2009.04.001_bib143","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.neuroscience.2008.08.041","article-title":"Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice","volume":"157","author":"Hickey","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbadis.2009.04.001_bib144","series-title":"Society for Neuroscience Abstracts","article-title":"Dose ranging and efficacy study of high-dose creatine in Huntington's disease mouse models","author":"Foran","year":"2006"},{"key":"10.1016\/j.bbadis.2009.04.001_bib145","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.neuroscience.2004.10.037","article-title":"Neuronal internuclear inclusions and neuropil aggregates in HdhCAG(150) knockin mice","volume":"131","author":"Talaksen-Greene","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbadis.2009.04.001_bib146","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","article-title":"A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration","volume":"23","author":"Hodgson","year":"1999","journal-title":"Neuron"},{"key":"10.1016\/j.bbadis.2009.04.001_bib147","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2009.04.001_bib148","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.brainresbull.2006.10.018","article-title":"Selective degeneration in YAC mouse models of Huntington's disease","volume":"72","author":"Van Raamsdonk","year":"2007","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.bbadis.2009.04.001_bib149","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0896-6273(02)00615-3","article-title":"Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease","volume":"33","author":"Zeron","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.bbadis.2009.04.001_bib150","doi-asserted-by":"crossref","first-page":"13614","DOI":"10.1523\/JNEUROSCI.3455-07.2007","article-title":"Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease","volume":"27","author":"Fernandes","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib151","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","article-title":"Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice","volume":"28","author":"Gray","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib152","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/hmg\/ddg075","article-title":"Transgenic rat model of Huntington's disease","volume":"12","author":"von H\u00f6rsten","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2009.04.001_bib153","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1093\/hmg\/ddl394","article-title":"Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease","volume":"15","author":"Nguyen","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2009.04.001_bib154","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1523\/JNEUROSCI.22-09-03473.2002","article-title":"Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length","volume":"22","author":"de Almeida","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib155","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/nature06975","article-title":"Towards a transgenic model of Huntington's disease in a non-human primate","volume":"453","author":"Yang","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2009.04.001_bib156","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","article-title":"Therapeutic effects of cystamine in a murine model of Huntington's disease","volume":"22","author":"Dedeoglu","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib157","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","article-title":"Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2032dG","volume":"66","author":"Hersch","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2009.04.001_bib158","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbadis.2006.03.004","article-title":"Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice","volume":"1762","author":"Smith","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2009.04.001_bib159","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/j.1471-4159.2007.05032.x","article-title":"Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease","volume":"104","author":"Weiss","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2009.04.001_bib160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2005.01.024","article-title":"Early behavioral deficits in R6\/2 mice suitable for use in preclinical drug testing","volume":"20","author":"Hickey","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbadis.2009.04.001_bib161","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.10094","article-title":"Environmental enrichment slows disease progression in R6\/2 Huntington's disease mice","volume":"51","author":"Hockly","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2009.04.001_bib162","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1523\/JNEUROSCI.0590-05.2005","article-title":"Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease","volume":"25","author":"Van Raamsdonk","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib163","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1460-9568.2005.03895.x","article-title":"A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease","volume":"21","author":"Morton","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbadis.2009.04.001_bib164","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0166-4328(99)00072-8","article-title":"Use of SHIRPA and discriminant analysis to characterise marked differences in the behavioural phenotype of six inbred mouse strains","volume":"105","author":"Rogers","year":"1999","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbadis.2009.04.001_bib165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0304-3940(01)01885-7","article-title":"SHIRPA, a protocol for behavioral assessment: validation for longitudinal study of neurological dysfunction in mice","volume":"306","author":"Rogers","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbadis.2009.04.001_bib166","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1046\/j.1471-4159.2003.01706.x","article-title":"Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice","volume":"85","author":"Dedeoglu","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2009.04.001_bib167","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","article-title":"Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice","volume":"23","author":"Ferrante","year":"2003","journal-title":"J. Neurosci."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443909000908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443909000908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T23:08:44Z","timestamp":1739056124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443909000908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":167,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0925443909000908"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2009.04.001","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}